Summit Rock Advisors, LP - Q4 2021 holdings

$167 Million is the total value of Summit Rock Advisors, LP's 8 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 60.0% .

 Value Shares↓ Weighting
VTV BuyVANGUARD INDEX FDSvalue etf$60,898,000
+29.2%
413,962
+18.9%
36.37%
+30.1%
IUSV  ISHARES TRcore s&p us vlu$56,506,000
+7.7%
740,1950.0%33.75%
+8.4%
IWN SellISHARES TRrus 2000 val etf$47,071,000
-29.0%
283,472
-31.5%
28.12%
-28.6%
CLOV  CLOVER HEALTH INVESTMENTS CO$784,000
-49.6%
210,6390.0%0.47%
-49.3%
PHAT  PHATHOM PHARMACEUTICALS INC$671,000
-38.7%
34,1000.0%0.40%
-38.2%
DAWN NewDAY ONE BIOPHARMACEUTICALS I$558,00033,125
+100.0%
0.33%
MNDY NewMONDAY COM LTD$517,0001,676
+100.0%
0.31%
DYN NewDYNE THERAPEUTICS INC$415,00034,887
+100.0%
0.25%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-02-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ISHARES TR29Q3 202090.6%
ISHARES TR26Q4 202051.7%
ISHARES INC11Q1 202064.0%
ISHARES TR11Q4 202147.6%
ISHARES TR9Q2 201534.5%
PHATHOM PHARMACEUTICALS INC9Q2 20221.1%
ISHARES TR RUS 2000 VAL ETF7Q4 202247.0%
SELECT SECTOR SPDR TR ENERGY6Q3 202367.4%
VANGUARD INTL EQUITY INDEX F5Q3 202245.3%
VANGUARD INDEX FDS4Q4 202136.4%

View Summit Rock Advisors, LP's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-01-26
13F-HR2023-10-24
13F-HR2023-07-21
13F-HR2023-05-09
13F-HR2023-01-12
13F-HR2022-11-02
13F-HR2022-08-01
13F-HR2022-05-06
13F-HR2022-02-14
13F-HR2021-10-26

View Summit Rock Advisors, LP's complete filings history.

Compare quarters

Export Summit Rock Advisors, LP's holdings